Drug intelligence / Profile preview

AH008

Development stage: Preclinical
Lead developer: Apricity Health

Overview

AH008 is a preclinical-stage precision oncology therapeutic candidate being developed by Apricity Health. It is part of a pipeline of therapies designed to treat cancer patients who do not respond to or have developed resistance to existing standard-of-care treatments. The drug was identified using Apricity Health's proprietary platform, which integrates human real-world data (RWD) with blood-based biomarkers to discover and validate novel targets driving treatment resistance. As of early 2024, AH008 is in the early stages of preclinical development, focusing on target validation and establishing proof-of-concept.

Beyond the preview

Go deeper on AH008.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AH008.

Explore the full profile